NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

MediPharm Labs Corp. (LABS.TO) Stock Analysis

MediPharm Labs Corp. (LABS.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

LABS.TO

CA$0.065

CA$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LABS.TO with… →

LABS.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$0.065
Previous Close
CA$0.065
Day's Range
0.065–0.07
52-Week Range
0.06–0.10
Volume
210.22K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
CA$27.77M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.67
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.01
Financials (FY)
Revenue (FY)
CA$45.12M+7.54%
Net Income (FY)
−CA$8.27M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
427.18M
1-Year Return
−18.75%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
121.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LABS.TO closed at CA$0.065, −18.75% over 1 year.

MediPharm Labs Corp. (LABS.TO) has a market capitalization of CA$27.77M.

In fiscal 2025, LABS.TO reported revenue of CA$45.12M.

LABS.TO Stock Return by Calendar Year

MediPharm Labs Corp. (LABS.TO) return since Mar 2019: what CA$10,000 became

1 year
CA$10,000 CA$8,125
−18.75%
5 years
CA$10,000 CA$2,321
−76.79%
Since Mar 2019
CA$10,000 CA$205
−97.95%

If you had invested CA$10,000 in MediPharm Labs Corp. (LABS.TO) at the close on March 4, 2019, the earliest close on record here, it would have been worth CA$205 at the close on October 21, 2026: −97.95% in total, −39.90% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.00%
2025+8.33%
2024−7.69%
2023−7.14%
2022−62.16%
2021−65.09%
2020−86.27%
2019 (partial year)+21.77%

As of October 21, 2026.

LABS.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$45.12M−CA$8.27M−18.3%
2024CA$41.96M−CA$10.69M−25.5%
2023CA$33.06M−CA$13.08M−39.6%
2022CA$22.12M−CA$29.98M−135.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$45.12MCA$13.97M−CA$8.41M−CA$8.27M−18.3%
2024CA$41.96MCA$12.81M−CA$10.89M−CA$10.69M−25.5%
2023CA$33.06MCA$5.86M−CA$17.75M−CA$13.08M−39.6%
2022CA$22.12M−CA$1.91M−CA$28.78M−CA$29.98M−135.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LABS.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricLABS.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.672.100.3x the median
Profit margin−12.00%−8.14%3.9 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

MediPharm Labs Corp. (LABS.TO) carries a market capitalisation of CA$27.77M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 127.

Over the past 52 weeks the price has ranged from CA$0.06 to CA$0.10. LABS.TO last closed at CA$0.065 on October 21, 2026. The close was unchanged from the previous session. The latest close sits 8.33% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$45.12M. Against the prior fiscal year total of CA$41.96M, that is a change of +7.54%. The same year closed with a net loss of CA$8.27M. Profit margin runs at −12%. That is 3.9 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.01.

Across the 4 fiscal years on file, revenue moves from CA$22.12M in 2022 to CA$45.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.67. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.85. Annualized volatility over the trailing 7 years is 86.99%. Over the trailing twelve months the total return is −18.75%. Measured over 5 years, that is −25.33% a year compounded.

Growth & Income

No dividend is on file for LABS.TO.

So far in 2026 the total return is 0.00%. The strongest complete calendar year on file is 2025 at +8.33%; the weakest is 2020 at −86.27%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

MediPharm Labs Corp. (LABS.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MediPharm Labs Corp. LABS.TO CA$27.77M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. MediPharm Labs Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MediPharm Labs Corp.

MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis products. In addition, the company offers cannabis related medical information and services; and cannabis clinic services for patients requiring medical cannabis education and prescriptions. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.

Visit website →